National Cancer Institute (NCI)–designated cancer centers shape cancer care in the United States and are supported by substantial public funds (in fiscal year 2018, $330 million in core funding for 70 cancer centers).1 Cancer care is also shaped by industry, because developing new cancer therapeutics represents a major market opportunity. Industry payments to academic physicians risk blurring the line between innovation and the evaluation of new therapies. We used Open Payments data from the Centers for Medicare & Medicaid Services (CMS) to examine industry payments made to physician directors of NCI-designated cancer centers.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Carr D, Welch HG. Industry Payments to Physician Directors of National Cancer Institute–Designated Cancer Centers, 2015-2017. JAMA Intern Med. Published online August 05, 2019. doi:10.1001/jamainternmed.2019.3098
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: